Cite
MLA Citation
Andre Goy et al.. “A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.” British journal of haematology, vol. 174, 2016, pp. 571–581. http://access.bl.uk/ark:/81055/vdc_100035003993.0x000055